In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains

Virology Journal

Volumn 4, Issue , 2007, Pages

  Pignolet, Béatrice ^a   Duteyrat, Jean Luc ^a,b   Allemandou, Aude ^a,b   Gelfi, Jacqueline ^a   Foucras, Gilles ^a   Bertagnoli, Stéphane ^a  

^a CNRS   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL INTERACTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; IN VITRO STUDY; MYXOMA; MYXOMA VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SWINE; VACCINATION; VIRION; VIRUS STRAIN; WILD TYPE; ANIMAL; CATTLE; CELL LINE; MONONUCLEAR CELL; PHYSIOLOGY; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; VIROLOGY; VIRUS ENTRY;

ANIMALIA; BOVINAE; MYXOMA VIRUS; POXVIRIDAE;

ANIMALS; CATTLE; CELL LINE; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, ELECTRON, TRANSMISSION; MYXOMA VIRUS; RABBITS; VIRUS INTERNALIZATION;

EID: 35748986109     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-94     Document Type: Article

References (20)

1. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. MP Kieny P Lathe R Drillien D Spehner S Skory D Schmitt T Wiktor H koprowski JP Lecocq, Nature 1984 312 163 166 10.1038/312163a0 6548799
2. Fowlpox virus as a vector in non-avian species. J Taylor E Paoletti, Vaccine 1988 6 466 8 10.1016/0264-410X(88)90091-6 2854335
3. Recombinant fowlpox virus inducing protective immunity in non-avian species. J Taylor R Weinberg B Languet P Desmettre E Paoletti, Vaccine 1988 6 497 503 10.1016/0264-410X(88)90100-4 2854338
4. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Tartaglia O Jarrett JC Neil P Desmettre E Paoletti, J Virol 1993 67 2370 2375 8383248
5. Host range restricted, non replicating vaccinia virus vectors as vaccine candidates. B Moss MW Carroll LS Wyatt JR Bennink VM Hirsch S Goldstein WR Elkins TR Fuerst JD Lifson M Piatak NP Restifo W Overwijk R Chamberlain SA Rosenberg G Sutter, Adv Exp Med Biol 1996 397 7 13 8718576
6. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-defecient vaccine vector. K Aspen J Passmore F Tiedt A Williamson, J Gen Virol 2003 84 1985 1996 10.1099/vir.0.19116-0 12867628
7. Disseminated vaccinia in military recruit with human immunodeficiency virus (HIV) disease. RR Redfield DC Wright WD James TS Jones C Brown DC Burke, N Engl J Med 1987 316 673 676 3821799
8. Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. S Bertagnoli J Gelfi G Le Gall E Boilletot J Vautherot D Rasschaert S Laurent F Petit C Boucraut-Baralon A Milon, J Virol 1996 70 5061 5066 8764013
9. Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus. J Barcena M Morales B Vazquez JA Boga F Parra J Lucientes A Pages-Mante JM Sanchez-Vizcaino R Blasco JM Torres, J Virol 2000 74 3 1114 23 10.1128/JVI.74.3.1114-1123.2000 10627521
10. Vaccination of cats with an attenuated myxoma virus expressing feline calicivirus capsid protein. VJ McCabe I Tarpey N Spibey, Vaccine 2002 20 2454 2462 10.1016/S0264-410X(02)00186-X 12057600
11. Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein. VJ McCabe N Spibey, Vaccine 2005 23 46-47 5380 5388 10.1016/j.vaccine.2005.05.038 16176851
12. Myxomatosis. F Fenner J Ross, The European Rabbit, the History and Biology of a Successful Colonizer Oxford, New York, Tokyo: Oxford University Press, Thompson GV, king CM, 1994 205 239
13. Myxoma virus tropism in human tumor cells. J Sypula F Wang Y Ma J Bell G Mcfadden, Gene Ther Mol Biol 2004 8 103 114
14. Etude d'une souche de virus myxomateux modifié P Saurat Y Gilbert JP Ganière, Rev Med Vet 1978 129 415 451 (In French)
15. Ultrastructure study of myxoma virus morphogenesis. JL Duteyrat J Gelfi S Bertagnoli, Arch Virol 2006 151 11 2161 2180 10.1007/s00705-006-0791-2 16763732
16. Vaccinia virus tropism for hematolymphoid cells is determined by restricted expression of a unique virus receptor. A Chahroudi R Chavan N Koyz EK Waller G Silvestri NB Feinberg, J Virol 2005 79 16 10397 10407 16051832 10.1128/JVI.79.16.10397-10407.2005
17. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. MW Carroll B Moss, Virology 1997 238 198 211 10.1006/viro.1997.8845 9400593
18. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected cells. JC Gallego-Gomez C Risco D Rodriguez P Cabezas S Guerra JL Carrascosa M Esteban, J Virol 2003 77 19 10606 10622 12970445 10.1128/JVI.77.19.10606-10622.2003
19. Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from Hela cells. A Meiser C Sancho J Krijnse-Locker, J Virol 2003 77 9931 9942 12941903 10.1128/JVI.77.18. 9931-9942.2003
20. Modified vaccinia virus-Ankara multiplies in rat IEC-6 cell and limited production of mature virions occurs in other mammalian cell lines. MI Okeke O Nilssen T Traavik, J Gen Virol 2006 87 21 27 10.1099/vir.0.81479-0 16361414